Skip to main content

Etihad Law

Home / Publications / Pharmaceuticals in Iraq

Pharmaceuticals in Iraq: Legal & Regulatory Guide

Registering, manufacturing, importing and selling pharmaceutical products in Iraq, from drug registration and pricing to KIMADIA tenders and controlled substances.

Talk to our team
25Topics covered
203+Questions answered
Federal & KRICoverage across Iraq
FreeRead online as a flipbook

About this guide

Legal and regulatory considerations for pharmaceuticals in Iraq

This guide examines the legal and regulatory considerations involved in registering, manufacturing, importing and selling pharmaceutical products in Iraq. It covers drug registration, market entry routes, scientific offices and commercial agents, joint ventures, local manufacturing and GMP requirements, wholesale and retail pharmacy licensing, pricing, and patents and data protection.

It also addresses import controls, cold chain and supply chain management, KIMADIA procurement, health financing and reimbursement, advertising and medical representatives, pharmacovigilance and recalls, clinical trials, controlled substances, biologics and biosimilars, OTC and herbal products, counterfeit medicines and parallel imports, pharmaceutical waste and trade remedies.

This publication provides general information only and does not constitute legal advice.

Contents

What this guide covers

01

Drug Registration in Iraq

7
  • Why does drug registration matter so much, and what is its legal basis in Iraq?

  • Who is allowed to apply for drug registration in Iraq?

  • What does the registration dossier need to include?

  • How does the IDCD review an application, and how long does the process take?

  • What obligations continue after a product is registered?

  • What can a company do if its registration application is refused?

  • What strategic considerations should a company keep in mind when registering a drug in Iraq?

02

Pharmaceutical Import Licences

8
  • What makes importing medicines into Iraq different from importing other goods?

  • Who is legally permitted to import pharmaceuticals into Iraq?

  • Is a general import licence enough, or does every shipment need its own permit?

  • Do narcotics, biologics, or cold chain products face additional import requirements?

  • What happens to a pharmaceutical consignment when it reaches the Iraqi border?

  • How does importing for the public sector through KIMADIA work?

  • What ongoing obligations does an importer have after customs clearance?

  • What are the consequences of non-compliance with Iraq's import regime?

03

Establish Pharmaceutical Manufacturing Facility

8
  • What does the path from project concept to an operating manufacturing facility look like in Iraq?

  • What legal structure should a pharmaceutical manufacturing investment use in Iraq?

  • Which authorities must approve a new pharmaceutical manufacturing facility, and in what order?

  • What GMP standards apply to facility design in Iraq?

  • What personnel does a licensed manufacturing facility need to appoint?

  • What happens during the pre-licensing GMP inspection, and how long does the certificate last?

  • Once the facility is licensed, can it start selling its products immediately?

  • What practical challenges should investors expect when manufacturing pharmaceuticals in Iraq?

04

Counterfeit & Substandard Medicines

7
  • What is the difference between counterfeit and substandard medicines, and why does the distinction matter?

  • What laws govern counterfeit and substandard medicines in Iraq?

  • Which authorities enforce action against counterfeit medicines in Iraq?

  • What can an original manufacturer do if its products are being counterfeited?

  • Does international cooperation play a role in fighting counterfeit medicines affecting Iraq?

  • Can patients harmed by counterfeit or substandard medicines bring their own claims?

  • What preventive measures should companies put in place against counterfeiting?

05

Pharmaceutical Pricing Regulation

6
  • Can pharmaceutical companies set their own prices in Iraq?

  • How does the Ministry of Health determine an approved price?

  • How are margins set through the distribution chain?

  • What is involved in submitting a pricing application, and can prices be changed later?

  • What strategic implications does the pricing system have for companies entering Iraq?

  • How are pharmaceutical pricing disputes resolved in Iraq?

06

Patent Protection for Pharmaceutical Products

8
  • What law governs pharmaceutical patents in Iraq, and what can be patented?

  • What are the patentability requirements, and how long does protection last?

  • Can a company file an international (PCT) application to obtain patent protection in Iraq?

  • What is data exclusivity, and does it apply in Iraq?

  • Can a generic product be registered while a patent is still in force?

  • How are pharmaceutical patents enforced in Iraq?

  • Does Iraqi law allow compulsory licensing of pharmaceutical patents?

  • Are further reforms to Iraq's patent system expected, and what strategic steps should companies take?

07

Clinical Trials

8
  • What approvals are needed before a clinical trial can start in Iraq?

  • What must a clinical trial protocol cover?

  • What are the informed consent requirements for trial participants?

  • Do investigational products need separate import permits?

  • What obligations do sponsors and investigators carry during a trial?

  • How quickly must adverse events be reported during an Iraqi trial?

  • What insurance and data protection requirements apply to clinical trials?

  • What happens when a clinical trial is completed?

08

Pharmaceutical Distribution & Wholesale Licensing

7
  • What role does the wholesaler play in Iraq's pharmaceutical supply chain?

  • What premises and personnel requirements apply to a licensed wholesaler?

  • What does Good Distribution Practice require of a wholesaler?

  • What do Ministry of Health inspections of wholesalers typically look for?

  • Are wholesaler margins and distribution agreements regulated in Iraq?

  • Who is liable when something goes wrong in the distribution chain?

  • What does it take to run a compliant drugstore operation day to day?

09

Foreign Pharmaceutical Companies Entering the Iraqi Market

9
  • Why is Iraq an attractive but challenging pharmaceutical market for foreign companies?

  • What are the main options for a foreign pharmaceutical company entering Iraq?

  • What should a company know about appointing a commercial agent in Iraq?

  • Is a scientific office mandatory for a foreign manufacturer?

  • Can a foreign pharmaceutical company set up a subsidiary or branch in Iraq?

  • What do joint ventures offer a foreign company entering Iraq?

  • What compliance areas apply across all entry routes?

  • How significant is anti-corruption compliance for pharmaceutical companies in Iraq?

  • Why should exit planning be considered at the time of market entry?

10

Pharmacovigilance & Post-Market Drug Safety

8
  • What is pharmacovigilance, and why has it become so important in Iraq?

  • Who is responsible for pharmacovigilance obligations in Iraq?

  • What are the timelines for reporting adverse events?

  • What does an adequate pharmacovigilance system look like?

  • When are Periodic Safety Update Reports and Risk Management Plans required?

  • How are drug recalls classified and managed in Iraq?

  • What are the requirements for communicating new safety information?

  • What are the consequences of pharmacovigilance failures?

11

Medical Insurance & Drug Reimbursement

8
  • How is healthcare financed in Iraq, and why does it matter to pharmaceutical companies?

  • What role does private health insurance play in Iraq's pharmaceutical market?

  • How does private-sector reimbursement of medicines work?

  • How does public sector (KIMADIA) procurement affect access to medicines?

  • How significant is out-of-pocket spending on medicines in Iraq?

  • How should manufacturers plan their commercial strategy around the payer mix?

  • What legal issues arise at the intersection of insurance, procurement, and pharma commercial practice?

  • What reforms in health financing should pharmaceutical companies watch for?

12

Narcotics & Controlled Substances

8
  • Why are narcotics and psychotropic substances regulated so much more strictly than ordinary medicines?

  • What does a substance's "schedule" determine?

  • What extra requirements apply to manufacturing and importing controlled substances?

  • How is domestic distribution of controlled substances restricted?

  • What rules apply to prescribing and dispensing controlled substances?

  • What penalties apply for non-compliance with the narcotics framework?

  • What should a compliance program for controlled substances include?

  • Does Iraq's geography create particular cross-border risks, and how are essential pain medicines balanced against abuse controls?

13

Advertising & Promotion of Medicines

10
  • Why is pharmaceutical advertising regulated so tightly in Iraq?

  • What core principles govern promotional claims for medicines?

  • Is direct-to-consumer advertising of medicines allowed in Iraq?

  • What rules apply to promoting medicines to healthcare professionals?

  • What rules govern providing free samples to healthcare professionals?

  • What are the rules on hospitality and sponsorship of medical events?

  • How is scientific information distinguished from promotion?

  • How does Iraqi law treat digital and social media promotion of medicines?

  • How does advertising regulation intersect with anti-corruption law?

  • What penalties apply for non-compliant pharmaceutical advertising?

14

Pharmacy Licensing & Operations

8
  • What legal framework governs retail pharmacies in Iraq?

  • Who can own a retail pharmacy in Iraq?

  • What is required to license a retail pharmacy?

  • What operational duties does a pharmacist have when dispensing medicines?

  • What personnel rules apply to pharmacy operating hours and dispensing?

  • Is selling medicines outside a licensed pharmacy legal in Iraq?

  • What do Ministry of Health and Syndicate inspections of pharmacies look for?

  • What commercial considerations and technology trends affect pharmacy operations?

15

Herbal & Traditional Medicine Regulation

8
  • Why does classifying a herbal product correctly matter so much in Iraq?

  • When is a herbal product classified as a pharmaceutical rather than a food or cosmetic?

  • What makes standardizing herbal products particularly challenging?

  • How are herbal dietary supplements regulated differently from herbal medicines?

  • What documentation is required to import herbal products into Iraq?

  • What GMP challenges do herbal medicine manufacturers face?

  • What rules apply to advertising herbal and traditional medicines, and what quality risks concern regulators?

  • What intellectual property protection is available for herbal products, and what market entry strategies work best?

16

Parallel Imports of Medicines

8
  • What is a parallel import of medicine, and how does Iraq treat it?

  • Why does Iraq take such a restrictive approach to parallel imports?

  • How does trademark and patent law affect parallel imports?

  • What public health concerns arise from parallel imports?

  • How is action taken against parallel imports enforced in Iraq?

  • In what practical scenarios do parallel imports typically arise?

  • What can manufacturers do to reduce parallel import incidence?

  • What risk does sourcing from unauthorized suppliers create for distributors and pharmacies?

17

Biosimilars & Biologics Regulation

8
  • Why do biologic medicines raise distinctive regulatory challenges in Iraq?

  • How does registering a biologic differ from registering a conventional medicine?

  • What does GMP inspection for biologic manufacturing involve?

  • What must a biosimilar application demonstrate, and how is the reference product chosen?

  • Can a pharmacist substitute a biosimilar for the reference biologic in Iraq?

  • What is the regulatory status of advanced therapies like gene and cell therapy in Iraq?

  • Are pharmacovigilance requirements different for biologics?

  • How does pricing and IP protection work for biologics and biosimilars in Iraq?

18

Cold Chain & Storage Requirements for Pharmaceuticals

8
  • Why is the cold chain both a technical and a legal compliance issue in Iraq?

  • Who is legally responsible for maintaining the approved storage condition of a medicine?

  • What must a cold chain storage facility have in place?

  • What are the requirements for transporting temperature-sensitive medicines?

  • What documentation must accompany cold chain products, and what happens during a temperature excursion?

  • Are vaccines treated differently under Iraq's cold chain rules?

  • What cold chain responsibilities fall on pharmacies and hospitals at the point of dispensing?

  • What do inspections typically find, and what are the consequences of a cold chain failure?

19

Pharmaceutical Tenders & Government Procurement (KIMADIA)

8
  • What is KIMADIA, and why does it matter to pharmaceutical companies?

  • What does prequalification for KIMADIA involve?

  • How does the KIMADIA tender and bidding process work?

  • How does KIMADIA evaluate and award tenders?

  • What should a supplier expect once a KIMADIA contract is awarded?

  • How are disputes with KIMADIA resolved?

  • What anti-corruption risks are specific to KIMADIA procurement?

  • What strategic considerations matter most for winning and keeping KIMADIA business?

20

Licensing Pharmaceutical Representatives & Medical Sales Agents

9
  • What role do pharmaceutical representatives play, and why does their conduct matter legally?

  • Do pharmaceutical representatives need to be licensed in Iraq?

  • What training obligations apply to medical representatives?

  • What conduct rules apply to representatives in the field?

  • What limits apply to samples, gifts, and hospitality provided by representatives?

  • Why does documentation of HCP interactions matter?

  • How does anti-corruption law affect representatives' interactions with HCPs?

  • What rules apply to representatives at congresses and in digital interactions?

  • What should a compliance program for medical representatives include, and what issues arise when employment ends?

21

Good Manufacturing Practice (GMP) Compliance

8
  • What is GMP, and what does it cover in Iraqi pharmaceutical manufacturing?

  • What does facility and equipment qualification involve under GMP?

  • What quality control standards must be met under Iraqi GMP?

  • Why is documentation so central to GMP compliance?

  • What role do personnel and quality culture play in GMP compliance?

  • How often does the Ministry of Health inspect manufacturing facilities, and what happens after an inspection?

  • What happens if a facility fails a GMP inspection?

  • How do foreign manufacturers and API suppliers demonstrate GMP compliance to Iraqi authorities?

22

Pharmaceutical Joint Ventures

9
  • Why do pharmaceutical companies use joint ventures in Iraq, and what forms do they take?

  • What legal vehicle is typically used for a pharmaceutical joint venture in Iraq?

  • How are capital contributions structured in a pharmaceutical joint venture?

  • What governance provisions matter most in a joint venture agreement?

  • What economic terms and technology/supply arrangements need attention?

  • How should non-compete and exclusivity clauses be handled?

  • What exit mechanisms should a joint venture agreement include?

  • How are disputes between joint venture partners typically resolved, and what regulatory approvals are needed?

  • Why do pharmaceutical joint ventures fail, and how can that be avoided?

23

Over-the-Counter (OTC) Medicines

9
  • What is the policy rationale behind the OTC category?

  • How does the Ministry of Health decide whether a medicine is OTC or prescription-only?

  • What are the labeling requirements for OTC products?

  • What rules govern advertising OTC medicines to the public?

  • Is OTC medicine pricing regulated?

  • What are the most common OTC categories, and do any of them carry special controls?

  • What is involved in switching medicine from prescription to OTC status?

  • What role does the pharmacist play in OTC use, and what does self-medication involve?

  • Do pharmacovigilance obligations apply to OTC medicines, and what should an OTC compliance program cover?

24

Pharmaceutical Waste Disposal & Environmental Compliance

9
  • Why is pharmaceutical waste regulated more strictly than ordinary commercial waste, and what laws apply?

  • Where does pharmaceutical waste come from across the supply chain?

  • How are different categories of pharmaceutical waste handled?

  • What disposal methods are permitted for pharmaceutical waste?

  • What obligations does a manufacturer have for managing its own waste?

  • What waste obligations apply to wholesalers, pharmacies, and hospitals, and to patient-returned medicines?

  • Are there special rules for destroying controlled substances or handling recalled stock?

  • What environmental compliance obligations apply to manufacturing facilities beyond waste disposal, and what emerging concerns should companies watch?

  • What penalties apply for non-compliance with pharmaceutical waste rules?

25

Anti-Dumping & Unfair Trade in Pharmaceuticals in Iraq

9
  • Why have trade remedies become relevant to Iraq's pharmaceutical sector?

  • What is "dumping" in the pharmaceutical trade context, and does Iraq have rules against it?

  • Why are anti-dumping concerns particularly sensitive for medicines?

  • How does an anti-dumping investigation typically start and proceed in Iraq?

  • What measures can be imposed as a result of a trade remedy investigation?

  • Should a domestic pharmaceutical manufacturer consider filing a trade remedy petition?

  • How should a foreign producer exporting to Iraq manage trade remedy risk?

  • How do public health considerations and customs valuation factor into pharmaceutical trade remedy decisions?

  • What developments should pharmaceutical companies watch for?

← All publications

Need advice on a specific matter?

This guide gives general information. Contact our team for advice tailored to your business.

Get in touch →